Fulgent Genetics, Inc.
FLGT
$18.50
$0.191.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 9.54% | 13.83% | 13.60% | 4.31% | 1.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.54% | 13.83% | 13.60% | 4.31% | 1.71% |
| Cost of Revenue | 9.69% | 8.82% | 4.65% | 2.70% | -0.44% |
| Gross Profit | 9.31% | 22.07% | 29.37% | 6.80% | 5.30% |
| SG&A Expenses | 26.66% | 27.15% | 6.49% | 4.70% | -1.11% |
| Depreciation & Amortization | 1.34% | 0.83% | 0.83% | 0.89% | 1.25% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.75% | 15.24% | 5.49% | 3.83% | 1.27% |
| Operating Income | -41.00% | -20.64% | 19.94% | -1.88% | 0.49% |
| Income Before Tax | -70.21% | -34.76% | 74.20% | 63.46% | 70.39% |
| Income Tax Expenses | -21.37% | -3.07% | 73.03% | -210.94% | -226.78% |
| Earnings from Continuing Operations | -79.13% | -40.65% | 74.31% | 69.52% | 75.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 9.12% | 0.54% | -83.02% | -86.10% | -84.95% |
| Net Income | -81.01% | -41.69% | 73.94% | 68.78% | 75.43% |
| EBIT | -41.00% | -20.64% | 19.94% | -1.88% | 0.49% |
| EBITDA | -61.73% | -32.78% | 26.20% | -6.64% | -3.00% |
| EPS Basic | -79.14% | -38.87% | 74.64% | 69.57% | 75.99% |
| Normalized Basic EPS | -78.12% | -37.47% | 24.23% | -16.99% | -4.05% |
| EPS Diluted | -79.08% | -38.85% | 74.63% | 69.58% | 76.00% |
| Normalized Diluted EPS | -78.12% | -37.47% | 24.23% | -16.99% | -4.05% |
| Average Basic Shares Outstanding | 0.95% | 1.80% | 2.27% | 2.33% | 2.20% |
| Average Diluted Shares Outstanding | 0.95% | 1.80% | 2.27% | 2.33% | 2.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |